Schizophrenia Clinical Trial
— CIRCUSOfficial title:
Study of the Effectiveness of a Guided Compensatory Cognitive Remediation Program for Family Caregivers in Schizophrenia: a Randomized Pilot Study
Cognitive impairments are extremely common in schizophrenia and strongly predict deficit in
daily functioning, the poor managing medication and multiple hospitalizations. Cognitive
remediation is recognized to have an impact on cognitive impairments by engaging preserved
cognitive functions or by implementing environmental supports that sustain independent
living.
Pr. Velligan (University of San Antonio) developed and tested a manualized intervention,
called Cognitive Adaptation Training. In this program, trained mental health specialists
implement compensatory technique such as environmental supports in the individual's living
environment to live more independently and achieve greater self-sufficiency.
However, implementing this program needs a lot of professionals and time to maintain CAT
effects. This type of intervention is not often done in community care and explains the large
number of patients who are dependent on family members for daily living activities. Training
family members in this form of intervention would be an appropriate way to resolve these
issues. Families expressed a real interest in these types of home-support strategies that CAT
offers. Recently, Pr. Kidd and Pr. Velligan developed a CAT version for families and created
a manual accessible to people without any knowledge of cognitive deficit. This manual helps
families to select specific cognitive-adaptative strategies with their relative to achieve
targeted goals. Thism ethod has been translated in French.
The aim of this study was to examine whether Web-based family Cognitive Adaptation Training
can improve functioning, medication adherence and negative symptoms for individuals with
schizophrenia and reduce burden for family members.
A total of 60 Dyads consisting of one caregiver and one supported individual with
schizophrenia will be randomized to either a Web-based family Cognitive Adaptation Training
or an Internet-based control condition. Primary outcome measured will be the score on the
life skills profile. Secondary outcomes will include the global score of the Zarit burden
Interview, PANSS negative score, and medication adherence.
This type of intervention is expected to be developed in territorial area where professionals
are not trained to cognitive remediation and therefore substantially lowers the barrier to
the deployment of cognitive intervention with other psychosocial interventions for individual
with schizophrenia and their caregivers.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | March 2021 |
Est. primary completion date | December 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Patient group : - Age = 18 years old and < 50 years old - patients with a diagnosis of schizophrenia according to the criteria of DSM 5 after evaluation by the investigating psychiatrist during the preliminary medical examination - patients who can understand, speak and read French - Patient who has given written informed consent to participate in the study, as well as written consent from the guardian for patients under guardianship, and/or from the trusted person for patients hospitalized in Third Party Request Psychiatric Care, Psychiatric Care at the request of a state representative and in a care program. If the patient is under curatorship, the curator will be informed of the study. - Subject's participation in the study noted in the medical file - Obligation to be a member or beneficiary of a social security scheme Family caregiver group : - The family carer is actively involved in the care of his or her relative with schizophrenia assessed by having at least one contact per week with the patient (Kidd et al., 2016). - The carer has an internet connection with a video chat application - Be under 75 years of age - Understand, read and speak French - Having signed an informed consent form - Obligation to be a member or beneficiary of a social security scheme The exclusion period during which recruited patients cannot be included in another protocol is one day after the end of the evaluations. This is specified on the consent form. Exclusion Criteria: - Patient group : - Patients with a history of severe head injury and/or neurological pathology with cognitive impact. - Patient who has benefited from individual or group cognitive remediation. Family caregiver group : - dementia diagnosis - a history of neurological pathology (epilepsy, multiple sclerosis, parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease) |
Country | Name | City | State |
---|---|---|---|
France | Service Universitaire de psychiatrie adulte | Montpellier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Life Skills Profile Score (LSP-39) | The "Life Scale Profile" (LSP), validated in French by Mohr et al (2004), is a scale used to assess the subject's life skills profile, particularly for patients with schizophrenia. It is a hetero-questionnaire based on the patient's functioning during the last week (excluding the acute or relapse phase). The scale is composed of 20 items picked-up in an ensemble of 39 questions. The instruction is to rate each item on a scale from 1 to 4: "always, usually, rarely and never". The lower the score, the more the patient has a deficit profile in terms of life. The maximum score is 80. The LSP scale assesses 5 subscores of life skills: sociability, self-management, treatment compliance, antisocial behaviours and strange behaviours. The total duration of the test is about 30 minutes. | Baseline | |
Primary | Life Skills Profile Score (LSP-39) | The "Life Scale Profile" (LSP), validated in French by Mohr et al (2004), is a scale used to assess the subject's life skills profile, particularly for patients with schizophrenia. It is a hetero-questionnaire based on the patient's functioning during the last week (excluding the acute or relapse phase). The scale is composed of 20 items picked-up in an ensemble of 39 questions. The instruction is to rate each item on a scale from 1 to 4: "always, usually, rarely and never". The lower the score, the more the patient has a deficit profile in terms of life. The maximum score is 80. The LSP scale assesses 5 subscores of life skills: sociability, self-management, treatment compliance, antisocial behaviours and strange behaviours. The total duration of the test is about 30 minutes. | 16 weeks | |
Primary | Life Skills Profile Score (LSP-39) | The "Life Scale Profile" (LSP), validated in French by Mohr et al (2004), is a scale used to assess the subject's life skills profile, particularly for patients with schizophrenia. It is a hetero-questionnaire based on the patient's functioning during the last week (excluding the acute or relapse phase). The scale is composed of 20 items picked-up in an ensemble of 39 questions. The instruction is to rate each item on a scale from 1 to 4: "always, usually, rarely and never". The lower the score, the more the patient has a deficit profile in terms of life. The maximum score is 80. The LSP scale assesses 5 subscores of life skills: sociability, self-management, treatment compliance, antisocial behaviours and strange behaviours. The total duration of the test is about 30 minutes. | 6 months | |
Secondary | Global score of the Zarit burden interview | Zarit's burden scale (Zarit et al., 1980; Hébert et al., 1993 for the French version) is a 22-item self-questionnaire measuring the burden experienced by a caregiver of an individual with a chronic disorder. The total score, which is the sum of the scores obtained for each of 22 items, varies from 0 to 88; a score less than or equal to 20 indicates a low or zero load; a score between 21 and 40 indicates a low load; a score between 41 and 60 indicates a moderate load; a score greater than 60 indicates a high load. | Baseline | |
Secondary | Global score of the Zarit burden interview | Zarit's burden scale (Zarit et al., 1980; Hébert et al., 1993 for the French version) is a 22-item self-questionnaire measuring the burden experienced by a caregiver of an individual with a chronic disorder. The total score, which is the sum of the scores obtained for each of 22 items, varies from 0 to 88; a score less than or equal to 20 indicates a low or zero load; a score between 21 and 40 indicates a low load; a score between 41 and 60 indicates a moderate load; a score greater than 60 indicates a high load. | 16 weeks | |
Secondary | Global score of the Zarit burden interview | Zarit's burden scale (Zarit et al., 1980; Hébert et al., 1993 for the French version) is a 22-item self-questionnaire measuring the burden experienced by a caregiver of an individual with a chronic disorder. The total score, which is the sum of the scores obtained for each of 22 items, varies from 0 to 88; a score less than or equal to 20 indicates a low or zero load; a score between 21 and 40 indicates a low load; a score between 41 and 60 indicates a moderate load; a score greater than 60 indicates a high load. | 6 months | |
Secondary | Patient quality of life: S-QoL 18 | The quality of life of patients is assessed by the Quality of Life Scale (S-QoL 18) is a shortened version of the S-QoL 41 scale whose validity and psychometric properties have been validated in patients with schizophrenia. The self-administered questionnaire assesses the impact of patients' difficulties on their quality of life through 8 dimensions: psychological well-being, self-esteem, family relationships, friendly relationships, resilience, physical well-being, autonomy and emotional life. The duration of the test is 7 minutes. | Baseline | |
Secondary | Patient quality of life: S-QoL 18 | The quality of life of patients is assessed by the Quality of Life Scale (S-QoL 18) is a shortened version of the S-QoL 41 scale whose validity and psychometric properties have been validated in patients with schizophrenia. The self-administered questionnaire assesses the impact of patients' difficulties on their quality of life through 8 dimensions: psychological well-being, self-esteem, family relationships, friendly relationships, resilience, physical well-being, autonomy and emotional life. The duration of the test is 7 minutes. | 16 weeks | |
Secondary | Patient quality of life: S-QoL 18 | The quality of life of patients is assessed by the Quality of Life Scale (S-QoL 18) is a shortened version of the S-QoL 41 scale whose validity and psychometric properties have been validated in patients with schizophrenia. The self-administered questionnaire assesses the impact of patients' difficulties on their quality of life through 8 dimensions: psychological well-being, self-esteem, family relationships, friendly relationships, resilience, physical well-being, autonomy and emotional life. The duration of the test is 7 minutes. | 6 months | |
Secondary | Caregiver quality of life: S-QoL 18 | The quality of life of caregivers is assessed by the Quality of Life Scale: As for patients, we will use the Quality of Life Scale (S-QoL 18). The self-administered questionnaire assesses the impact of patients' difficulties on their quality of life through 8 dimensions: psychological well-being, self-esteem, family relationships, friendly relationships, resilience, physical well-being, autonomy and emotional life. The duration of the test is 7 minutes. | Baseline | |
Secondary | Caregiver quality of life: S-QoL 18 | The quality of life of caregivers is assessed by the Quality of Life Scale: As for patients, we will use the Quality of Life Scale (S-QoL 18). The self-administered questionnaire assesses the impact of patients' difficulties on their quality of life through 8 dimensions: psychological well-being, self-esteem, family relationships, friendly relationships, resilience, physical well-being, autonomy and emotional life. The duration of the test is 7 minutes. | 16 weeks | |
Secondary | Caregiver quality of life: S-QoL 18 | The quality of life of caregivers is assessed by the Quality of Life Scale: As for patients, we will use the Quality of Life Scale (S-QoL 18). The self-administered questionnaire assesses the impact of patients' difficulties on their quality of life through 8 dimensions: psychological well-being, self-esteem, family relationships, friendly relationships, resilience, physical well-being, autonomy and emotional life. The duration of the test is 7 minutes. | 6 months | |
Secondary | Negative symptoms | Clinical Assessment Interview for Negative symptoms (CAINS) (Kring et al., 2013). CAINS is a recently developed tool to evaluate the 2 dimensions of negative symptomatology highlighted in the literature, i.e. the motivation dimension and the decreased emotional expressivity dimension. It has been translated into French by our team (Raffard et al., currently under validation). It includes 13 items (9 for the amotivation dimension and 4 for the expressivity dimension) evaluated during a semi-structured interview. | Baseline | |
Secondary | Negative symptoms | Clinical Assessment Interview for Negative symptoms (CAINS) (Kring et al., 2013). CAINS is a recently developed tool to evaluate the 2 dimensions of negative symptomatology highlighted in the literature, i.e. the motivation dimension and the decreased emotional expressivity dimension. It has been translated into French by our team (Raffard et al., currently under validation). It includes 13 items (9 for the amotivation dimension and 4 for the expressivity dimension) evaluated during a semi-structured interview. | 6 months | |
Secondary | Patient compliance | Medication Adherence Rating Scale (Misdrahi et al., 2004). This scale is one of the most widely used tools to assess compliance in individuals with schizophrenia. This is a self-administered questionnaire with 10 yes/no items offering a total score from 0 (low compliance) to 10 (high compliance). | Baseline | |
Secondary | Patient compliance | Medication Adherence Rating Scale (Misdrahi et al., 2004). This scale is one of the most widely used tools to assess compliance in individuals with schizophrenia. This is a self-administered questionnaire with 10 yes/no items offering a total score from 0 (low compliance) to 10 (high compliance). | 16 weeks | |
Secondary | Patient compliance | Medication Adherence Rating Scale (Misdrahi et al., 2004). This scale is one of the most widely used tools to assess compliance in individuals with schizophrenia. This is a self-administered questionnaire with 10 yes/no items offering a total score from 0 (low compliance) to 10 (high compliance). | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |